Bank of America’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Bank of America’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-39	Closed	-$8K	–	7464
2018 Q3	$8K	Buy	+39	New	+$93.6K	﹤0.01%	6732

Other funds holding ONCT

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Bank of America's ONCT Position: Q4 2024 in Review

Bank of America sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 22 shares — an estimated $29 sold.

Bank of America first reported a position in ONCT in Q2 2013 and held it in 41 quarters. The position peaked at $423K in Q2 2013. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

Bank of America reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Bank of America sold 22 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $29.
Bank of America first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 41 quarters.
Bank of America's Oncternal Therapeutics, Inc. Common Stock position peaked at $423K in Q2 2013.
4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.